New technologies now allow life sciences companies to pursue “outcomes-based” commercial models that directly tie their reimbursements to the real-world outcomes their patients experience. Such arrangements are likely to revolutionize the industry. While companies focused on certain therapeutic areas will adapt first, all companies will eventually need to capitalize on digital investments to define, monitor and improve patient outcomes. Those that embrace the outcomes-based commercial opportunity early will have the best chance of not only regaining control of key profitability levers, but also influencing the industry’s shift to a healthier financial model.
VIEW THE REPORT [PDF]